Analysts Offer Predictions for SABS Q2 Earnings

SAB Biotherapeutics, Inc. (NASDAQ:SABS) – HC Wainwright issued their Q2 2025 earnings per share estimates for SAB Biotherapeutics in a research note issued on Wednesday, May 14th. HC Wainwright analyst E. Bodnar expects that the company will post earnings of ($0.58) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $10.00 price target on the stock. The consensus estimate for SAB Biotherapeutics’ current full-year earnings is ($3.69) per share. HC Wainwright also issued estimates for SAB Biotherapeutics’ Q3 2025 earnings at ($0.44) EPS, Q4 2025 earnings at ($0.39) EPS, FY2025 earnings at ($1.85) EPS, FY2026 earnings at ($0.35) EPS, FY2027 earnings at ($0.25) EPS, FY2028 earnings at ($0.33) EPS and FY2029 earnings at ($0.42) EPS.

SAB Biotherapeutics (NASDAQ:SABS) last released its quarterly earnings data on Friday, May 9th. The company reported ($0.56) EPS for the quarter, beating the consensus estimate of ($1.00) by $0.44. SAB Biotherapeutics had a negative net margin of 1,450.14% and a negative return on equity of 94.37%.

Separately, Chardan Capital reiterated a “buy” rating and set a $20.00 price objective on shares of SAB Biotherapeutics in a research note on Thursday. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, SAB Biotherapeutics has an average rating of “Buy” and an average target price of $12.20.

SAB Biotherapeutics Stock Performance

NASDAQ SABS opened at $1.85 on Friday. The stock has a 50-day simple moving average of $1.52 and a two-hundred day simple moving average of $2.52. The firm has a market capitalization of $17.19 million, a P/E ratio of -0.50 and a beta of 0.47. SAB Biotherapeutics has a fifty-two week low of $1.00 and a fifty-two week high of $5.01. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.69 and a current ratio of 3.69.

Institutional Trading of SAB Biotherapeutics

Institutional investors have recently bought and sold shares of the business. Northern Trust Corp acquired a new position in shares of SAB Biotherapeutics during the 4th quarter worth about $43,000. Geode Capital Management LLC increased its stake in shares of SAB Biotherapeutics by 18.8% in the 4th quarter. Geode Capital Management LLC now owns 80,234 shares of the company’s stock worth $307,000 after acquiring an additional 12,692 shares during the last quarter. Silver Oak Securities Incorporated purchased a new position in shares of SAB Biotherapeutics during the 1st quarter worth $30,000. HB Wealth Management LLC boosted its position in shares of SAB Biotherapeutics by 10.9% during the 1st quarter. HB Wealth Management LLC now owns 263,200 shares of the company’s stock valued at $358,000 after acquiring an additional 25,800 shares during the last quarter. Finally, Diadema Partners LP purchased a new stake in shares of SAB Biotherapeutics in the fourth quarter valued at about $114,000. 7.82% of the stock is owned by institutional investors and hedge funds.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.